Quan Jing Wang·2025-10-27 23:10Group 1 - The core viewpoint of the news highlights the dual role of CITIC Securities as both a sponsor and shareholder in the IPOs of Xi'an Yicai and Bibete, showcasing confidence in the companies with a combined shareholding value of approximately 800 million yuan [1][2] Group 2 - Xi'an Yicai is the largest 12-inch silicon wafer manufacturer in mainland China, focusing on R&D and production, with a market value of 34.806 billion yuan at the time of IPO application [1] - The company aims to break the monopoly of overseas firms and has achieved global leading levels in key performance indicators, with a planned production capacity of 710,000 wafers per month by the end of 2024, accounting for about 7% of the global market [1] - CITIC Securities holds 2.2% of Xi'an Yicai, making it the largest shareholder, with a shareholding value of approximately 76.573 million yuan [1] Group 3 - Bibete, founded in 2012, focuses on innovative drug development for oncology and autoimmune diseases, with its core product BEBT-908 already approved for lymphoma treatment [1] - The company is preparing to initiate Phase III trials for its promising pipeline drug BEBT-209, which has shown superior clinical data for metastatic triple-negative breast cancer compared to existing therapies [1] - CITIC Securities holds 0.5206% of Bibete, with a shareholding value of approximately 3.333 million yuan [1] Group 4 - CITIC Securities' dual role in sponsoring and holding shares reflects its strategic positioning in the hard technology sector, particularly in semiconductor material localization and innovative drug development [2] - The firm aims to facilitate the capital realization of innovative results while participating deeply in industrial upgrades, promoting synergy between finance and the real economy [2]